Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1995;92:2855-2862

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arstall, M. A.
Right arrow Articles by Horowitz, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arstall, M. A.
Right arrow Articles by Horowitz, J. D.

(Circulation. 1995;92:2855-2862.)
© 1995 American Heart Association, Inc.


Articles

N-Acetylcysteine in Combination With Nitroglycerin and Streptokinase for the Treatment of Evolving Acute Myocardial Infarction

Safety and Biochemical Effects

Margaret A. Arstall, MBBS; Jeifu Yang, MD; Irene Stafford, BS; W. Henry Betts, PhD; John D. Horowitz, MBBS, PhD

From the Cardiology Unit (M.A.A., J.Y., I.S., J.D.H.) and the Rheumatology Unit (W.H.B.), The Queen Elizabeth Hospital, University of Adelaide, South Australia, Australia.

Correspondence to Prof J.D. Horowitz, Senior Director, Cardiology Unit, The Queen Elizabeth Hospital, 28 Woodville Rd, Woodville South, South Australia 5011, Australia.

Background N-acetylcysteine (NAC) has been shown to potentiate the effects of nitroglycerin (NTG) and to have antioxidant activity. This is the first study to assess the safety and effect of NAC in the treatment of evolving acute myocardial infarction (AMI).

Methods and Results Patients with AMI received either 15 g NAC infused over 24 hours (n=20) or no NAC (n=7), combined with intravenous NTG and streptokinase. Peripheral venous plasma malondialdehyde (MDA), reduced (GSH) and oxidized (GSSG) glutathione concentrations, and rate of reperfusion (using continuous ST-segment analysis) were measured. Cardiac catheterization was performed between days 2 and 5. No significant adverse events occurred. Less oxidative stress occurred in patients treated with NAC than in patients not receiving NAC (GSH to GSSG ratio 44±25 versus 19±13 at 4 hours, P<.05). NAC concentration (mean 172±79 µmol/L at 4 hours) was correlated to GSH concentration (P=.006). MDA concentrations were lower (P=.001) over the first 8 hours of treatment with NAC. There was a trend toward more rapid reperfusion (median 58 minutes, 95% confidence interval [CI] 48 to 98 minutes versus median 95 minutes, 95% CI 59 to 106 minutes; P=.17) and better preservation of left ventricular function (cardiac index 3.4±0.8 versus 2.6±0.27 L · min · m2, P=.009) with NAC treatment.

Conclusions NAC in combination with NTG and streptokinase appeared to be safe for the treatment of evolving AMI and was associated with significantly less oxidative stress, a trend toward more rapid reperfusion, and better preservation of left ventricular function.


Key Words: free radicals • reperfusion • myocardial infarction




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
A. B. Gustafsson and R. A. Gottlieb
Heart mitochondria: gates of life and death
Cardiovasc Res, January 15, 2008; 77(2): 334 - 343.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
M. Rudnick and H. Feldman
Contrast-Induced Nephropathy: What Are the True Clinical Consequences?
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 263 - 272.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. W.A. Verheugt
Response to Letter Regarding Article, "Reperfusion Starts in the Ambulance"
Circulation, December 12, 2006; 114(24): e641 - e641.
[Full Text] [PDF]


Home page
NEJMHome page
G. Marenzi, E. Assanelli, I. Marana, G. Lauri, J. Campodonico, M. Grazi, M. De Metrio, S. Galli, F. Fabbiocchi, P. Montorsi, et al.
N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.
N. Engl. J. Med., June 29, 2006; 354(26): 2773 - 2782.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
N. Pannu, N. Wiebe, M. Tonelli, and for the Alberta Kidney Disease Network
Prophylaxis Strategies for Contrast-Induced Nephropathy
JAMA, June 21, 2006; 295(23): 2765 - 2779.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
L. G. Kevin, E. Novalija, and D. F. Stowe
Reactive Oxygen Species as Mediators of Cardiac Injury and Protection: The Relevance to Anesthesia Practice
Anesth. Analg., November 1, 2005; 101(5): 1275 - 1287.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
T. G. Gleeson and S. Bulugahapitiya
Contrast-Induced Nephropathy
Am. J. Roentgenol., December 1, 2004; 183(6): 1673 - 1689.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
L. F. Drager, L. Andrade, J. F. Barros de Toledo, F. R. M. Laurindo, L. A. Machado Cesar, and A. C. Seguro
Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury
Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1803 - 1807.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
U. M. Fischer, C. S. Cox Jr, S. J. Allen, R. H. Stewart, U. Mehlhorn, and G. A. Laine
The antioxidant N-acetylcysteine preserves myocardial function and diminishes oxidative stress after cardioplegic arrest
J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1483 - 1488.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. Kay, W. H. Chow, T. M. Chan, S. K. Lo, O. H. Kwok, A. Yip, K. Fan, C. H. Lee, and W. F. Lam
Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and Intervention: A Randomized Controlled Trial
JAMA, February 5, 2003; 289(5): 553 - 558.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K.-G. i Shyu, J.-J. Cheng, and P. Kuan
Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure
J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1383 - 1388.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Sochman
N-acetylcysteine in acute cardiology: 10 years later: What do we know and what would we like to know?!
J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1422 - 1428.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. Safirstein, L. Andrade, and J. M. Vieira
Acetylcysteine and Nephrotoxic Effects of Radiographic Contrast Agents -- A New Use for an Old Drug
N. Engl. J. Med., July 20, 2000; 343(3): 210 - 212.
[Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Z. Ungvari, P. Pacher, K. Rischak, L. Szollar, and A. Koller
Dysfunction of Nitric Oxide Mediation in Isolated Rat Arterioles With Methionine Diet–Induced Hyperhomocysteinemia
Arterioscler. Thromb. Vasc. Biol., August 1, 1999; 19(8): 1899 - 1904.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. P. Reilly, N. Delanty, L. Roy, J. Rokach, P. O. Callaghan, P. Crean, J. A. Lawson, and G. A. FitzGerald
Increased Formation of the Isoprostanes IPF2{alpha}-I and 8-Epi-Prostaglandin F2{alpha} in Acute Coronary Angioplasty : Evidence for Oxidant Stress During Coronary Reperfusion in Humans
Circulation, November 18, 1997; 96(10): 3314 - 3320.
[Abstract] [Full Text]